![]() senescence-associated secretory phenotype (SASP)). that disturb the tissue micro-environment (a.k.a. These cells accumulate in the body, secreting large quantities of proteins, including inflammatory cytokines, proteases, immune modulators, growth factors, etc. ![]() What are senescent cells? They are cells that have permanently halted division. The scientists at Unity believe that the accumulation of senescent cells is a fundamental mechanism of aging and a causal factor in many common age-related diseases and have made this tenet the foundation of their research efforts. As such, providing healthcare for people over the age of 65 costs four to five times more than the balance of the population, which is why the healthcare system is essentially bankrupt. Approximately 80% of individuals over the age of 65 have at least one chronic disease and 50% suffer from two or more. The Theoryįor those not familiar with the first report, Unity has spent its existence identifying the root causes of age-related diseases, which burden the healthcare system at an increasing rate as people age. It was relatively low on cash (runway into mid-2022) and its stock was trading at $62.10. When we last looked at Unity in March 2021, it was still reeling from the failure of osteoarthritis candidate UBX0101 in August 2020, compelling it to restructure itself to focus on UBX1325, which had only entered the clinic in October 2020. Its stock trades around $4.50 a share, equating to an approximate market cap of $65 million. Unity was formed in 2009 and went public in 2018, raising net proceeds of $75.9 million at $170 per share, after giving effect to a 1-for-10 reverse split in October 2022. The company has one clinical asset that is currently pursuing two ophthalmology indications. ( NASDAQ: UBX) is a South San Francisco based mid-clinical-stage healthcare concern developing treatments that “ slow, halt, or reverse diseases of aging ,” with a current focus on ophthalmology. ![]() Therefore, we revisit Unity with this updated analysis below. ![]() That turned out to be the right call as the stock has seen a sharp sell-over since we posted our initial research on this company. We concluded that initial article on this developmental concern by noting ' We’ll keep an eye on this one as Unity is theoretically promising, but more is needed in practice before getting excited about this early-stage busted IPO. It has been nearly two years since our first look at Unity Biotechnology. Strong men believe in cause and effect.”― Ralph Waldo Emerson Shallow men believe in luck or in circumstance. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |